Webinars & Presentations

Key case studies are presented by Dr. Hyatt Want at Stanford University (Crystal Mackall & Steve Feldman Labs), Dr. Elena Stoyanova at Touchlight Genetics, and Dr. Marianna Romito at MaxCyte. Each presenter shares data on how to increase engineering efficiency in primary and stem cells, all while maintaining high cell viability and recovery for applications in gene editing and autologous/allogeneic cell therapy.

The High Efficiency Cell Engineering Seminar was hosted at the University of Pennsylvania on Friday, October 27, 2023, with our special guest, Nils Wellhausen, who is co-mentored by Drs. Carl June and Saar Gill, recently published a novel therapeutic strategy for the treatment of most blood cancers. This presentation showcased the development of fratricide-resistant, base-edited CD45-targeting CAR T cells and CD45 epitope-edited hematopoietic stem cells. This approach paves the way forward for a universal blood cancer immune therapy.

Register to delve into the future of cellular engineering by viewing the on demand seminar on Non-viral Cell Engineering from Catamaran, CCRM and MaxCyte. Our special guest, Catamaran Bio, will showcase their innovative, transposon-based approach to CAR-NK cell engineering and demonstrate how MaxCyte and CCRM scientists helped enable their clinical development and advancement.

Learn how to drive your biologics development forward by leveraging MaxCyte^® Flow Electroporation^® technology. This flexible, scalable technology enables alternative strategies for the rapid development of high-yielding stable cell lines and can deliver gram-scale transient protein production within two weeks. Hosted with Labroots on September 12, 2023.

Hosted at Stanford University on July 6, 2023. Access this on demand seminar and learn more about how academic & industry labs utilize MaxCyte’s platforms to efficiently engineer primary cells, stem cells, and cell lines all while maintaining high cell viabilities & recovery for applications such as CRISPR, cell-based assays, protein production, viral production and more.

Non-viral site directed CAR integration can be accomplished using CRISPR/Cas9 and double-stranded DNA (dsDNA) via homology-directed repair (HDR), however yields with this approach have been limiting for clinical application. We discuss here a targeted but HDR-independent approach for the manufacture of CAR-T cell therapies – Presented during JSGE, June 2023

Global Challenges, Opportunities, and Views from the United States, Europe, and Asia – Presented during ASGCT 2023

Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The quality of CAR-T cell products, including T-cell memory signatures and exhaustion-related markers, is critical for the function of CAR-T cell therapies. We have developed novel piggyBac transposon (PB) -based CAR-T cells with favorable characteristics and durable antitumor efficacy against solid malignancies. Webinar broadcasted on Labroots March 30, 2023.

Abstract: Recent breakthroughs in autologous cellular therapies have generated tremendous excitement for the industry; however, these advances have been confronted with the expense of manufacturing of viral gene delivery and concerns over random integration and the safety of viral vectors. To combat these challenges, researchers at the University of California San Francisco have developed a novel system that offers lower toxicity with a single-stranded DNA (ssDNA) approach. This webinar was broadcasted on Labroots on May 24th, 2022.